secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001213900-25-002831
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna outlines 2025 priorities; pivotal SPS trial 40% enrolled, BLA filing targeted for 2026
--------------------------------------------------------------------------------

- 40% enrolled in pivotal Phase 2 KYV-101 trial for stiff person syndrome; BLA filing targeted for 2026.
- Cash runway into 2027 with $321.6M cash and securities as of Sep 30, 2024.
- Myasthenia gravis: confirm registrational path 1H 2025, interim Phase 2 data 2H 2025.
- Lupus nephritis: Phase 1 data expected 2H 2025; KYV-102 IND filing 2H 2025.
- Company pivoting to late-stage development and commercialization with CD19 CAR T construct KYV-101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/0001213900-25-002831-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000121390025002831/ea0227480-8k_kyverna.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-002831

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer